GLI1, a terminal effectors of the HH factors, was reported to serve as an oncogene in wide ranges of cancers, such as breast cancer (47), CRC (48), prostate cancer (49), glioma (50), pancreatic cancer (51), gastric cancer (52), and cervical cancer (53). Here, GLI1 is linked to central nervous system cancer.